How Adult Stem Cells Are Obtained from the Body

Adult stem cells are harvested from several body tissues, but the three most common routes are bone marrow aspiration, mobilized peripheral blood collection, and liposuction of fat tissue. Each method targets a different cell population, carries its own recovery profile, and suits different clinical goals. The choice depends on what type of stem cell is needed, how many cells are required, and whether the procedure has to happen in an operating room or can be done at a bedside.

Bone Marrow Aspiration

Bone marrow remains the oldest and most familiar source of adult stem cells. A physician inserts a hollow needle, usually into the back of the pelvic bone (the iliac crest), and draws out a small volume of marrow fluid. That fluid contains mesenchymal stem cells, blood-forming progenitor cells, and a cocktail of growth factors that support tissue repair.¹ The procedure is typically done under local anesthesia, sometimes with light sedation, and takes roughly 15 to 30 minutes.

A practical detail that affects cell quality is how the needle is handled during the draw. Studies comparing single-site versus multiple-site needle insertions found that puncturing several spots on the pelvis produced more pain both during and 24 hours after the procedure.² For orthopedic applications like cartilage repair, clinicians often aspirate a concentrated sample and process it on the spot. For transplant purposes, larger volumes are collected under general anesthesia in an operating room.

Mobilized Peripheral Blood Collection

Blood-forming stem cells normally sit deep inside bone marrow, but they can be coaxed into the bloodstream with medication. The standard approach involves injecting a growth factor called G-CSF (filgrastim) for several days beforehand. This floods the marrow with signals that push stem cells out into circulating blood, where they can be collected without any bone puncture at all.

When G-CSF alone does not push enough cells into circulation, a second drug called plerixafor can be added. Plerixafor works by blocking the molecular anchor that keeps stem cells tethered inside the marrow, causing a rapid release of cells into the bloodstream.³ The effect is fast and reversible, and the combination of G-CSF plus plerixafor tends to work better than either drug on its own.⁴

Once the cells are circulating, they are collected through apheresis, a process that looks a lot like blood donation. Blood is drawn from one arm, passed through a machine that separates out the stem-cell-rich layer, and the remaining blood components are returned through the other arm. A single session typically runs about four hours. In one series of 39 procedures, the median apheresis session lasted about 240 minutes and collected roughly 220 milliliters of cell product, with about two-thirds of sessions reaching the target cell dose needed for transplant.⁵ Donors do lose some platelets in the process, but those rebuild on their own within days.

Harvesting From Fat Tissue

Adipose tissue, the fat just beneath your skin, turns out to be a rich reservoir of mesenchymal stem cells. Collecting them resembles a cosmetic liposuction procedure: a surgeon injects a fluid to loosen the tissue, then suctions it out through a thin tube called a cannula. The aspirated fat is processed to separate out a cell mixture known as the stromal vascular fraction, which contains stem cells, endothelial progenitor cells, and immune cells.

How the fat is collected matters. A comparison of harvesting techniques found that direct surgical excision of fat yielded significantly more stem cells than standard liposuction, while the commonly used Coleman technique (a manual syringe method with centrifugation) produced more total stromal cells than excision but not more actual stem cells.⁶ In practice, liposuction is far less invasive than excision, so most clinical protocols accept the lower per-gram yield and simply collect more tissue to compensate.

Fat-derived stem cells also come from different anatomical sites with different results. Lipoaspirate from the abdomen or thighs tends to produce higher initial cell counts, but fat harvested from other depots, such as the fat pad below the kneecap, may have different functional properties after processing.⁷ The clinical question is not just “how many cells can I get” but “how well will these cells do the job I need.”

Less Common Sources

Bone marrow, blood, and fat dominate clinical use, but adult stem cells hide in smaller niches throughout the body. Researchers have successfully isolated stem cells from dental tissues, including the pulp inside teeth, the tissue surrounding an impacted wisdom tooth, and the root tip. These populations can be separated when wisdom teeth are extracted, cultured, and grown into usable quantities.⁸ Dental stem cells are particularly interesting because they share some properties with neural cells, making them a research target for nerve repair.

Hair follicles are another accessible niche. Stem cells have been cultured from plucked scalp hairs, and a mechanical isolation method using punch biopsies can extract follicular stem cells without any culture step at all.⁹¹⁰ Skin biopsies also yield keratinocyte stem cells, which are extracted using enzyme-based digestion of a small skin sample and then cultured.¹¹ These skin-derived cells are primarily used in burn treatment, where sheets of cultured skin cells can cover large wound areas.

Animal studies comparing stem cells from different tissue types found that the synovial membrane lining joints produced colonies at a rate roughly 100-fold higher than bone marrow per nucleated cell, and that cells from solid tissues generally proliferated better than bone marrow cells.¹² These alternative sources are still largely in the research phase for human therapies, but they hint at a future where the best source for a given patient depends on the specific repair needed.

Processing and Purification After Collection

Raw tissue or blood collected from the body is a messy mixture. Stem cells make up a tiny fraction of what comes out. In peripheral blood, for instance, the target cells represent less than 0.2% of white blood cells.¹³ Separating them requires laboratory processing.

The most common first step is density gradient centrifugation, where the cell mixture is layered over a dense solution and spun. Different cell types settle into different bands based on their weight, and the stem-cell-rich band is collected. More recently, tube-based systems have been developed to speed this step up while keeping the process more standardized.¹⁴

For higher purity, magnetic bead separation is widely used. Tiny magnetic particles coated with antibodies bind to a specific marker on the surface of the target cells. The mixture is then passed through a magnetic column, which traps the labeled cells while everything else washes through. This approach can enrich the target cell population from under 1% to over 50% in a single pass, and a second round of sorting with a fluorescence-based cell sorter can push purity above 98%.¹³

The surface markers used to identify different stem cell types matter here. Mesenchymal stem cells, for example, are defined by expressing certain surface proteins and lacking others. The standard panel includes positive markers like CD105, CD73, and CD90, plus the absence of blood cell markers like CD45 and CD34.¹⁵ Confirming this profile is how labs verify that what they have isolated is actually a stem cell population and not contaminating blood cells or other tissue debris.

How Donor Age and Body Composition Affect the Harvest

Not all donors produce equally useful cells. Advancing age is the most consistently documented factor working against stem cell quality. Mesenchymal stem cells isolated from older donors show hallmarks of cellular aging: they grow more slowly in culture, they are less likely to survive, and they are less capable of turning into specialized cell types like bone or cartilage.¹⁶

A comparison of adipose-derived stem cells found that cells from donors under 30 proliferated faster and differentiated more readily into fat cells than those from donors over 50.¹⁷ Body mass index also plays a role in unexpected ways: higher BMI was associated with enhanced bone-forming potential, possibly because the fat tissue in heavier individuals is metabolically different. These donor-specific variables are something clinicians have to weigh when planning autologous therapies, where you are both the donor and the recipient. If you are older or have certain health conditions, the cells you produce may need longer culture expansion or supplementation with growth factors to reach the same therapeutic potency.

Safety and Recovery

Both bone marrow and peripheral blood donation are safe procedures, but their recovery profiles differ meaningfully. A Cochrane review comparing the two found that bone marrow donors experienced more pain at the collection site, more overall adverse events, and more days of restricted activity. They were also more likely to need hospitalization. Peripheral blood donors, by contrast, experienced more pain before collection, likely caused by the G-CSF injections used to mobilize their cells.¹⁸

Data from the National Marrow Donor Program put numbers to this pattern. Among bone marrow donors, about 82% reported back or hip pain at the aspiration site, while 97% of peripheral blood donors reported bone pain during the days of G-CSF injections. Fatigue was the second most common complaint for both groups. The key practical difference was recovery time: peripheral blood donors recovered in a median of one week, compared to three weeks for marrow donors. Serious adverse events were uncommon in both groups but occurred more often in marrow donors, at a rate of about 1.3% versus 0.6% for peripheral blood donors.¹⁹

Fat harvesting carries risks similar to any liposuction procedure: bruising, swelling, infection at the cannula site, and rarely fluid imbalances. Because the volumes collected for stem cell purposes tend to be smaller than cosmetic liposuction, the complication rates are generally low.

Freezing and Storing Cells

Stem cells often need to be banked for later use, which means freezing them without destroying their ability to function. The standard cryoprotectant has long been DMSO (dimethyl sulfoxide), mixed with serum and cooled at a controlled rate of about one degree Celsius per minute before being plunged into liquid nitrogen at around minus 196 degrees.

Researchers have been working to reduce the amount of DMSO needed, partly because DMSO can cause side effects when thawed cells are infused into patients. One study found that adipose-derived stem cells frozen with just 2% DMSO in a serum-free medium survived at roughly the same rate as cells frozen with the conventional 10% DMSO plus serum: about 84% viability in both cases.²⁰ A similar study on bone marrow mesenchymal stem cells showed that cutting DMSO to 7.5% and adding a polymer called PEG preserved about 83% viability, matching the conventional formula.²¹

Alternatives to DMSO are also being tested. Polyvinylpyrrolidone (PVP), a polymer already used in pharmaceutical products, achieved about 70% viability when used as a stand-in for DMSO, compared to about 83% with DMSO-based formulas.²² That gap is meaningful for clinical use, but the cells retained their ability to differentiate into bone and fat, suggesting PVP could serve patients who cannot tolerate DMSO. The broader trend is toward simpler, serum-free, lower-DMSO freezing recipes that make stem cell banking safer and more standardized.

Automated and Point-of-Care Systems

Traditional stem cell processing requires a specialized lab, trained technicians, and hours of manual work. That is fine for a transplant center, but it limits access for same-day surgical applications like orthopedic repair or wound healing. Automated point-of-care devices are changing that picture.

One closed, automated system designed to process up to 500 milliliters of lipoaspirate uses a filtration-based approach to isolate the stromal vascular fraction in the operating room. Testing showed that its cell yield and viability matched manual processing, with over 90% cell viability and equivalent proportions of the key cell types.²³ In an animal study, a similar automated system produced cells that improved the performance of synthetic vascular grafts when applied during surgery, confirming that machine-processed cells could work in a real-time clinical setting.²⁴

These devices reduce the need for a separate cell-processing lab, shrink the time between harvest and application, and lower costs. They also help navigate a tricky regulatory issue.

The Regulatory Line Between Minimal and More-Than-Minimal Manipulation

Regulators in the United States, Europe, and elsewhere draw a sharp line between “minimally manipulated” tissue and anything that has been substantially altered. If you take fat tissue, rinse it, and inject it back into the same patient without breaking it down into individual cells, many regulatory agencies consider that minimal manipulation. The moment you add enzymes to digest the tissue and isolate specific cell populations, the product crosses into “more than minimal” territory and is subject to the same regulatory scrutiny as a manufactured drug.²⁵

This distinction has spawned an entire field of mechanical processing methods designed to stay on the “minimal” side of the line. Instead of enzymatic digestion, these approaches use shaking, centrifugation, or filtration to break apart fat tissue and concentrate the stem-cell-rich fraction. The trade-off is generally a lower and less pure cell yield compared to enzymatic methods, but the regulatory path is dramatically shorter: no clinical trial approval needed in some jurisdictions, which means faster access for patients. The automated point-of-care systems described above were partly developed with this regulatory reality in mind. For researchers and clinicians, the method of obtaining stem cells is not just a biological question but a legal and commercial one, and the regulatory classification of a cell product can determine whether a therapy reaches patients in two years or ten.